Soleno Therapeutics Inc (SLNO) Gets a Buy Rating from Maxim Group


Maxim Group analyst Caroline Palomeque maintained a Buy rating on Soleno Therapeutics Inc (SLNO) today and set a price target of $4. The company’s shares closed yesterday at $2.04.

Palomeque wrote:

“Soleno reported 3Q18, spending $3.9M in operating expenses and ending the period with $10.2M in cash, sufficient runway to reach the next inflection point, the P3 data for diazoxide choline controlled-release (DCCR) tablets in Prader- Willi syndrome (PWS) expected in 1H19.”

According to TipRanks.com, Palomeque is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.5% and a 30.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Anavex Life Sciences, and Daré Bioscience Inc.

Currently, the analyst consensus on Soleno Therapeutics Inc is a Moderate Buy with an average price target of $4.

See today’s analyst top recommended stocks >>

Based on Soleno Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.74 million. In comparison, last year the company had a GAAP net loss of $3.58 million.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soleno Therapeutics, Inc. is a healthcare company, focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts